Livzon Pharmaceutical Group Inc.
000513 · SZSE
Public Market Listing
000513SZSE
Live quotes, historical charts, and market capitalization for Livzon Pharmaceutical Group Inc. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-17A/FMonoclonal antibody | Psoriasis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
1 June 2026Filing acceptedLecankitugNMPA accepts the marketing application for lecankitug in ankylosing spondylitis (CXSS2600087)
China, NMPA · Livzon Pharmaceutical Group Inc. · Source ↗
December 2025Filing acceptedLecankitug Injection (LZM012)NMPA accepts the marketing authorisation application for lecankitug (LZM012) in plaque psoriasis
CN, NMPA · Livzon MABPharm Inc. · Source ↗
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.7B | — | — | — | report ↗ |